Navigation Links
Moffitt Cancer Center researchers: Quality of life as important as quantity of life
Date:4/27/2012

Researchers at Moffitt Cancer Center have placed new emphasis on gathering data on cancer patient quality of life during both treatment and survivorship. Their focus is on gathering and using that data to develop interventions to improve the quality of life for patients in treatment and for cancer survivors.

Much of the quality of life and survivorship research is carried out by researchers in Moffitt's Department of Health Outcomes & Behavior.

"Among the several research goals of the Department of Health Outcomes & Behaviors is the evaluation and improvement of quality of life and quality of care," said department chair Thomas H. Brandon, Ph.D. "We aim to understand and improve a patient's quality of life throughout the disease course by identifying clinical practices and health outcomes that can inform our efforts to improve the quality of cancer care."

Quality of life should be considered

"The question of how well people are surviving cancer is as important as how long they survive cancer," said lead author Paul. B. Jacobsen, Ph.D., associate center director for Population Science, and Heather S.L. Jim, Ph.D., of Health Outcomes & Behaviors. Their study on patient quality of life was published in a recent issue of Cancer Epidemiology, Biomarkers & Prevention (2011; 20).

Assessment of quality of life factors is important, said the authors, but many of the measurements for assessing quality of life, particularly for cancer survivors, need development.

"Quality of life is a multidimensional construct about daily functioning - from physical to social - which is most often assessed by patient self-report," Jim said. "It is important that clinical trials include quality of life as an endpoint because if two treatments are found to work equally well, the treatment that offers the best quality of life for cancer survivors should be prescribed."

Prolonged fatigue after treatment

In a recent study published in Cancer, researchers from Moffitt found that when patients treated with chemotherapy or chemotherapy and radiation for breast cancer were compared to a control group who had not had cancer, the patients who had experienced chemotherapy and/or radiotherapy had more fatigue. These patients also had fatigue that lasted years after their therapy.

"This finding was contrary to our expectations," Jacobsen said. "Conventional thinking is that patients receiving chemotherapy would, over time, experience less fatigue and would eventually see their fatigue diminish to the levels of controls who had not had cancer, or to the level of fatigue they had prior to their chemotherapy."

One variable that could have affected the group with prolonged fatigue, noted the researchers, was a lack of supportive care, such as exercise and cognitive behavioral therapy. Interventions such as these could have an impact on patient fatigue and thus help improve quality of life, they noted.

Pain helped by psychosocial care

In a study published recently in the Journal of Clinical Oncology, Moffitt researchers who teamed with colleagues at five universities across the United States concluded that psychosocial interventions could have an effect on patient's pain severity during cancer treatment.

"Our study looked at randomized, controlled studies of psychosocial interventions for pain published between 1966 and 2010 in which pain was measured as an outcome for adults with cancer or those undergoing procedures to diagnose cancer," Jacobsen said.

When they analyzed 37 past studies, the researchers found that the most successful psychosocial, nonpharmacological interventions were skill-based or educational.

"Skill-based interventions focused on changing a patient's dysfunctional beliefs about pain and promoted the use of skills - such as distraction and relaxation - to manage it," explained Jacobsen. "We found that psychosocial interventions could improve pain severity and interference with daily activities."

Stigma affects quality of life of lung cancer patients

When Moffitt researchers Jacobsen and Brian D. Gonzalez, M.A., of Health Outcomes & Behavior, studied depression among patients with lung cancer, they found that perceived stigma related to their disease corresponded to greater levels of depression, and that patients with depression had more "dysfunctional attitudes."

"Given its strong association with tobacco use, lung cancer may be viewed as a preventable disease, so patients might blame themselves and feel stigmatized," explained Jacobsen.

The aim of the study, according to Gonzalez, was to examine rates of social rejection, financial insecurity, internalized shame and social isolation, and develop psychosocial interventions for depression.

"Therapy that focuses on altering the patient's thoughts and feelings associated with their perceptions of stigma could prove effective in reducing symptoms of depression and improve patient quality of life," Gonzalez said.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. New Moffitt Cancer Center patent promises to accelerate cancer trials
3. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
4. Fibroblasts contribute to melanoma tumor growth, say Moffitt Cancer Center researchers
5. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
6. Moffitt researchers will be strong participants in American Society of Hematology meeting
7. Moffitt Cancer Center researchers find MK1775 active against sarcomas
8. Moffitt Cancer Center researchers find men less willing to be screened for cancer
9. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
10. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
11. Moffitt Cancer Center researchers find more clues to causes of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Presence Technology ... has been included by Gartner, Inc. in the Contact Center Infrastructure Magic Quadrant ... Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web services interfaces, ...
(Date:5/31/2016)... ... 31, 2016 , ... St. Joseph Medical Center (SJMC) announced ... which enables physicians at SJMC’s two hospital campuses, downtown and in the Heights, ... the exchange. SJMC’s membership in the health information exchange underscores the hospital’s commitment ...
(Date:5/31/2016)... ... May 31, 2016 , ... The University of Tennessee Medical ... and the latest in Clinical Patient Pod (CPP) technologies provided through ... directly into the clinical workflow. These insights are empowering the more than 30 ...
(Date:5/31/2016)... ... 2016 , ... DDL, Inc. announced today it has expanded the scope of ... ISO 594-1 and ISO 594-2 testing for conical (Luer) fittings. , A conical ... medical devices (e.g. a syringe and hypodermic needle) that carry small volumes of fluids. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spartan Bioscience today introduced the ... and convenience. , The Cube is exceptionally small—it takes up the space of ... easily into any space, whether in a hospital, doctor’s office, or pharmacy. , ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 31, 2016 According to a ... (Scanners, Software), by Type (Human, Animal Pathology), by End ... Drug Discovery) - Global Forecasts to 2021", published by ... forecast period of 2016 to 2021. This market is ... USD 384.3 Million in 2016, at a CAGR of ...
(Date:5/31/2016)... 2016   Plexus Technology Group, LLC ... management systems (AIMS), is pleased to announce the ... President of Technology. In this new capacity, Mr. ... the company,s technological development. He will collaborate with ... the expansion of new products, product features and ...
(Date:5/31/2016)... BASEL, Switzerland , May 31, 2016 ... has announced the initiation of a first-in-human clinical trial ... class, fusion molecule - S101 is currently being developed ... phase 1 study is designed to evaluate the safety ... be conducted at several sites across the ...
Breaking Medicine Technology: